<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03431168</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-300001112</org_study_id>
    <nct_id>NCT03431168</nct_id>
  </id_info>
  <brief_title>A Novel Regimen to Prevent Malaria and STI in Pregnant Women With HIV</brief_title>
  <acronym>PREMISE</acronym>
  <official_title>The PREMISE Trial: A Novel Regimen to Prevent Malaria and Sexually Transmitted Infections in Pregnant Women With HIV</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      More than 3 billion people worldwide are at risk of acquiring malaria and pregnant women
      living with HIV in Africa are at particular risk. An effective prophylaxis regimen capable of
      preventing malaria and other common perinatal infections would have great potential to
      improve adverse birth outcomes. The purpose of this randomized controlled trial is to
      evaluate a new combination prophylaxis regimen in pregnant women with HIV in Cameroon to
      determine its efficacy and safety.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The World Health Organization (WHO) recommends malaria prophylaxis for all pregnant women
      living in endemic areas in order to reduce maternal anemia, low birth weight and perinatal
      mortality by 25-45%. The most commonly used regimen is intermittently dosed
      sulfadoxine-pyrimethamine (SP).Unfortunately, SP prophylaxis is contraindicated for
      HIV-infected pregnant women since co-administration with TMPS (trimethoprim-sulfamethoxazole)
      causes serious adverse events. TMPS (Bactrim or Cotrimoxazole) is an effective,
      well-tolerated, low-cost antibiotic that is used as prophylaxis in HIV-patients with low CD4
      counts. It has anti-malarial activity with prophylactic efficacy that is comparable to SP
      (30-90%). Daily TMPS is recommended as malaria prophylaxis in pregnant women with HIV in many
      African countries (including Cameroon) but malaria infection rates are high even when
      medication compliance is excellent; thus, new and improved options are urgently needed.
      Azithromycin (AZ) is a macrolide antibiotic with activity against malaria, a good safety
      profile in pregnancy and proven utility as a part of combination malaria prevention regimens
      (such as SP-AZ). It also has activity against sexually transmitted infections (STI) and
      perinatal pathogens, including chlamydia (CT), gonorrhea (GC), syphilis and GBS
      (Streptococcus agalactiae or Group B Streptococcus), a potential but understudied contributor
      to high rates of newborn sepsis and death in Africa. SP-AZ prophylaxis in HIV-uninfected
      pregnant women has been reported to reduce prevalence of low birth weight (RR 0.74, 95%
      confidence interval (CI) 0.6-0.9) and preterm delivery (RR 0.66, 95% CI 0.48-0.91) compared
      to SP alone.

      Thus, the central hypothesis is that a TMPS-AZ combination will be more effective than
      standard TMPS malaria prophylaxis in pregnant women with HIV, and that it will also decrease
      STI coinfection. Investigators plan a test-of-concept of the central hypothesis by conducting
      a double blinded, Phase II randomized controlled trial (RCT).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 7, 2018</start_date>
  <completion_date type="Anticipated">June 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasmodium falciparum peripheral parasitemia</measure>
    <time_frame>At end of pregnancy (&gt;35 weeks) or at delivery</time_frame>
    <description>P. falciparum detected by microscopy or polymerase chain reaction (PCR)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion with composite STI outcome</measure>
    <time_frame>will be measured in both groups (&gt;35 weeks) or at delivery</time_frame>
    <description>Including chlamydia (NAAT (nucleic acid amplification test) positive) , gonorrhea (NAAT positive), syphilis (non-treponemal and treponemal test positive) infections.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean infant birthweight</measure>
    <time_frame>at birth</time_frame>
    <description>Neonatal weight measured with digital scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion with adverse birth outcomes</measure>
    <time_frame>Birth outcomes will be measured at birth for all outcomes except early neonatal mortality defined as within 7 days of birth. Early neonatal mortality will be assessed at a six week follow up phone call.</time_frame>
    <description>Composite measure: low infant birthweight (&lt;2500 grams), miscarriage (&lt;28 weeks), preterm delivery (&lt;37 weeks), small for gestational age (SGA), congenital anomaly detected on surface examination, early neonatal mortality (within 7 days of birth)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal adherence to the prophylactic regimen</measure>
    <time_frame>Adherence will be documented from the date of randomization until the time of delivery, assessed up to 42 weeks.</time_frame>
    <description>Directly observed therapy (DOT) in clinic for the 1st dose of study medication. Self-report and pill count will be used to assess adherence and maternal tolerability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Episodes of symptomatic malaria</measure>
    <time_frame>From the date of randomization until the time of delivery, assessed up to 42 weeks.</time_frame>
    <description>Fever and positive malaria test (rapid diagnostic test) at routine visits or sick call visits or maternal report of malaria diagnosis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean geometric mean parasite density (GMPD) for Plasmodium falciparum</measure>
    <time_frame>At the end of pregnancy (&gt;35 weeks gestational age (GA)) or at delivery</time_frame>
    <description>Mean GMPD will be compared between the two study arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion with placental malaria</measure>
    <time_frame>At delivery</time_frame>
    <description>Placentas will be collected on a subset of women and impression smear will be used to assess for malaria infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion with maternal anemia and severe maternal anemia</measure>
    <time_frame>At the end of pregnancy (&gt;35 weeks) or at delivery</time_frame>
    <description>anemia defined as hemoglobin &lt;11 g/dL, severe anemia defined as hemoglobin &lt;7 g/dL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perinatal anogenital GBS colonization</measure>
    <time_frame>after 35 weeks GA or at delivery</time_frame>
    <description>Proportion of women in each arm with GBS detected by NAAT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite STI Measure (including all STI tests)</measure>
    <time_frame>After 35 weeks GA or at delivery</time_frame>
    <description>Proportion of women with GC/CT (by NAAT), syphilis (by serology), Mycoplasma genitalium (NAAT).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">310</enrollment>
  <condition>HIV</condition>
  <condition>Pregnancy Malaria</condition>
  <condition>Sexually Transmitted Infection</condition>
  <arm_group>
    <arm_group_label>Azithromycin/TMPS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Azithromycin 1 gm po daily x 3 days at enrollment and at each 4 week follow up visit.
TMPS double strength 1 tablet po daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo/TMPS</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Azithromycin placebo 1 gm po daily x 3 days at enrollment and at each 4 week follow up visit.
TMPS double strength 1 tablet po daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin/TMPS</intervention_name>
    <description>2 tabs po daily x 3 days at enrollment and at each monthly follow up visit</description>
    <arm_group_label>Azithromycin/TMPS</arm_group_label>
    <other_name>Cotrimoxazole</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo/TMPS</intervention_name>
    <description>2 tabs po daily x 3 days at enrollment and at each monthly follow up visit</description>
    <arm_group_label>Placebo/TMPS</arm_group_label>
    <other_name>Co-Trimoxazole</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed HIV-infection (documented in medical record)

          -  Age â‰¥16 years

          -  Confirmed pregnancy, &lt;28 weeks estimated gestational age (by best obstetric estimate
             which may include ultrasound or fundal height and LMP)

          -  Live singleton pregnancy

          -  Receiving prenatal care at Mboppi Hospital or Mutengene Hospital

          -  Plan to receive follow up prenatal care and deliver at study facility

          -  Capable of providing written informed consent

          -  Able and agree to come to facility for febrile episodes or acute illness during
             pregnancy (with reimbursement of transportation costs).

          -  Agree to avoid antimalarial medications outside of study protocol.

        Exclusion Criteria:

          -  Severe anemia (last hemoglobin &lt;6)

          -  History of severe adverse reaction to co-trimoxazole or azithromycin

          -  Active medical problem requiring inpatient evaluation at the time of screening

          -  Intention of moving far away from the facility during pregnancy or not likely to
             return for follow up care or delivery

          -  Signs or symptoms of early or active labor

          -  History of severe cardiac disease (including congestive heart failure, severe valvular
             disease or arrhythmias).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jodie A Dionne-Odom, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jodie A Dionne-Odom, MD</last_name>
    <phone>205 975 6530</phone>
    <email>jdionne@uabmc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jodie Dionne-Odom</last_name>
      <phone>205-975-6530</phone>
      <email>jdionne@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>Jodie A Dionne-Odom, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 2, 2018</study_first_submitted>
  <study_first_submitted_qc>February 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 13, 2018</study_first_posted>
  <last_update_submitted>March 19, 2018</last_update_submitted>
  <last_update_submitted_qc>March 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Jodie Dionne-Odom</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>STI Prevention</keyword>
  <keyword>Cameroon</keyword>
  <keyword>sub-Saharan Africa</keyword>
  <keyword>HIV pregnancy</keyword>
  <keyword>Malaria in pregnancy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Malaria</mesh_term>
    <mesh_term>Sexually Transmitted Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

